

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 59240

Title: Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension

Reviewer's code: 01705318

Position: Peer Reviewer

Academic degree: FCPS, FEBG, MD, PhD

Professional title: Professor, Research Scientist, Senior Scientist

Reviewer's Country/Territory: United States

Author's Country/Territory: China

Manuscript submission date: 2020-10-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-10-13 00:57

Reviewer performed review: 2020-10-27 09:23

Review time: 14 Days and 8 Hours

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Extremely interesting paper who investigate the impact on COVID-19 patients complicated with hypertension who discontinue using ACEIs/ARBs. Patients in discontinued ACEIs/ARBs group have longer hospital stays. This study suggests that COVID-19 patients complicated with hypertension should continue to use ACEIs/ARBs. Excellent paper. I have no other recommendations for improvement.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 59240

Title: Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension

Reviewer's code: 01524425

Position: Peer Reviewer

Academic degree: FRCPC, MD, PhD

Professional title: Associate Professor, Doctor, Research Scientist

Reviewer's Country/Territory: Germany

Author's Country/Territory: China

Manuscript submission date: 2020-10-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-10-13 00:58

Reviewer performed review: 2020-10-27 09:23

Review time: 14 Days and 8 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Recent studies have revealed that sustained ingesting angiotensin converting enzymes inhibitors or angiotensin receptor blockers (ACEIs/ARBs) had no harmful effects on COVID-19 patients complicated with hypertension. However, the impact of discontinue using ACEIs/ARBs in those patients still unclearly. Nonetheless, the authors believe that ACEIs/ARBs should be continued in patients with both COVID-19 and hypertension unless further evidence demonstrates adverse outcomes. Overall, the study is very well designed and the results are very interesting. The sample size is enough and methods are very clear. Discussion is good. I have a minor comment, the format of tables should be edited according to the standard format.